| Name | Title | Contact Details |
|---|
PharmaCord is the key connector between manufacturers, patients, physicians and payors. We provide innovative solutions that drive efficient and rapid access to life saving therapies. At PharmaCord, we help biopharma companies by delivering tailored solutions that alleviate product access hurdles and drive commercial success. Programs are configured with a focus on key stakeholders in a product`s success including physicians, patients and payors. Services are accessed through our CAPS (Centralized Access Patient Services) Center. Rapid uptake and continuation of therapy are the results our clients see. While the name of the company is new, our leadership is not. Over the years our team has provided support to millions of patients and driven commercial success for our client`s products. The leadership team of the company have led the launch of over 40 different products and transitioned dozens of programs spanning a 20-year period.
Tricida, Inc., is a pharmaceutical company focused on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a chronic condition commonly caused by CKD that is believed to accelerate the progression of CKD, increase the risk of muscle wasting and cause the loss of bone density. Tricida has successfully completed all of the clinical trials that it planned to complete prior to submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), including a successful 135-subject, Phase 1/2 clinical trial (TRCA-101), a successful 217-subject, pivotal Phase 3 clinical trial (TRCA-301), and a successful 196-subject, Phase 3 extension trial (TRCA-301E). We plan to submit an NDA, in the second half of 2019, seeking approval of TRC101 through the FDA`s Accelerated Approval Program. Tricida was founded in August 2013 by a seasoned management team that has extensive experience in the development and commercialization of therapeutics, with substantial expertise in developing polymers for the treatment of kidney-related diseases. Tricida`s shared culture of teamwork, camaraderie and empowerment is evident in the dedication and focus our team demonstrates, with a commitment to the ultimate goal of improving and prolonging the lives of people living with CKD, and bringing critically needed new therapies to patients.
We combine the personal care found in private dermatology practices with the benefits of a network of physicians working together.
Impel Pharmaceuticals specializes in Precision Olfactory Delivery (POD) nasal devices for Alzheimers, migraine, and other central nervous system diseases.
Harold Crossley is a Cockeysville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.